Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. by Galkin, Maria & Jonas, Brian A
UC Davis
UC Davis Previously Published Works
Title
Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-
based review of its place in therapy.
Permalink
https://escholarship.org/uc/item/6bd1r04k
Authors
Galkin, Maria
Jonas, Brian A
Publication Date
2019
DOI
10.2147/ce.s172912
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
R E V I EW
Enasidenib in the treatment of relapsed/refractory
acute myeloid leukemia: an evidence-based review
of its place in therapy
This article was published in the following Dove Press journal:
Core Evidence
Maria Galkin1
Brian A Jonas 2
1Department of Internal Medicine,
University of California Davis School of
Medicine, Sacramento, CA, USA;
2Department of Internal Medicine,
Division of Hematology and Oncology,
University of California Davis School of
Medicine, Sacramento, CA, USA
Introduction: Acute myeloid leukemia (AML) remains a disease with high mortality,
especially for older patients and those with relapsed/refractory (R/R) disease. With recent
advances in molecular testing, targeting particular leukemogenic mutations such as those
occurring in isocitrate dehydrogenase (IDH) became possible. Enasidenib is a new small-
molecule inhibitor of mutant isocitrate dehydrogenase-2 (IDH2).
Aim: The objective of this article is to review the evidence for the use of enasidenib in R/R
AML, as well as to outline future directions of enasidenib therapy.
Evidence Review: Enasidenib was approved in August 2017, after a successful Phase I/II
trial showing an overall response rate (ORR) of 40.3% in R/R disease, with 19.3% of patients
achieving complete remission (CR). Enrollees in the trial were mostly older adults. The most
prominent toxicities were hyperbilirubinemia and IDH-differentiation syndrome (IDH-DS),
though the drug was generally well tolerated and the maximum tolerated dose was not
reached. A Phase III trial is currently ongoing.
Conclusion: Enasidenib provides a new therapeutic option for patients with R/R AML.
Further studies are ongoing to ascertain its role in combination with other agents and newly
diagnosed disease.
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Core Evidence Clinical Impact Summary
Outcome
Measure
Evidence Implications
Disease-Oriented
Evidence
Relapsed/Refractory
IDH-2 mutated AML
Clinical
trial
The Phase II study of enasidenib showed an overall
response rate of 40.3%, including a 19.3% complete
remission rate as well as 6.8% complete remission with
incomplete count recovery rate. The median overall
survival was 9.3 months, and 19.7 months in those with
complete remission. Based on the outcome of this Phase
II trial, IDH2 inhibitors provide an additional therapeutic
option for patients with relapsed/refractory AML with an
IDH2 mutation. The Phase III trial (IDHENTIFY) is cur-
rently ongoing.
(Continued)
Correspondence: Brian A Jonas
UC Davis Comprehensive Cancer Center,
4501 X Street, Suite 3016, Sacramento,
CA, USA
Tel +1 916 734 3772
Fax +1 916 734 7946
Email bajonas@ucdavis.edu
Core Evidence Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Core Evidence 2019:14 3–17 3
DovePress © 2019 Galkin and Jonas. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/
terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing
the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://doi.org/10.2147/CE.S172912
Introduction
Acute myeloid leukemia (AML) is a heterogeneous hema-
tologic malignancy with high mortality, characterized by
excess clonal myeloid blasts that infiltrate the bone mar-
row and other tissues, as well as related cytopenias.
Patients can initially present with constitutional symptoms,
infection, bleeding or may be asymptomatic. Without ther-
apy, this disease is fatal usually due to infection or
hemorrhage.1 It therefore remains an urgent and complex
disease to treat.
Despite available therapy, long-term survival rates are
no higher than 45% for younger patients and 20% for older
patients.2,3 In refractory disease, long-term survival rates
are less than 10%.3 Thus, further research into new thera-
pies, especially for relapsed and/or refractory (R/R) AML,
are necessary.
The mainstay of initial treatment for eligible patients
remains cytotoxic chemotherapy with 7+3 (cytarabine
+anthracycline), which is used most commonly.4
Treatments for older patients can be more limited by
performance status and organ function, but can include
hypomethylating agents (HMA) such as azacitidine and
decitabine.4
With growing knowledge of driver mutations in AML
and new molecular testing (which is becoming standard at
many centers), there is an emerging landscape of addi-
tional targets for treatment. One such target is isocitrate
dehydrogenase 1/2 (IDH1/IDH2) mutations, seen in
approximately 20% (some figures as high as 33%) of
AML cases.5,6 Currently, there are two US Food and
Drug Administration (FDA) approved IDH inhibitors—
ivosidenib, an IDH1 inhibitor approved in 2018, and ena-
sidenib (AG-221), an IDH2 inhibitor approved in 2017.7,8
Here, we aim to review enasidenib and its potential in
treatment of relapsed and refractory AML.
AML background
Treatment of R/R AML
Relapsed and refractory AML poses an unfortunately com-
mon challenge to clinicians, with a typical median overall
survival of approximately 6 months with active therapy.9–11
Treatment decisions depend largely on patient factors, includ-
ing performance status, comorbidities and social support, as
well as disease factors, such as cytogenetics, molecular ana-
lysis, relapsed/refractory status and prior treatments. Goals of
therapy also differ for each patient, and may be allogeneic
transplant for the fit patient, versus extending life or improv-
ing the quality of life without transplant for the unfit.
For the fit patient with relapsed/refractory disease,
high-intensity options include salvage therapy with regi-
mens such as fludarabine, cytarabine and idarubicin
(FLAG-IDA), high-dose cytarabine and mitoxantrone, eto-
poside and cytarabine (MEC), among others, in prepara-
tion for allogeneic stem cell transplantation.4,12 For both
the fit and unfit patient, enrollment in an appropriate
clinical trial is recommended.2,13,14
(Continued).
Outcome
Measure
Evidence Implications
Treatment-naïve IDH-2
mutated AML
Clinical
trials
ongoing
● A Phase I study examining the use of IDH inhibitors,
including enasidenib, in combination with standard cyto-
toxic therapy is ongoing.
● A Phase I study pairing IDH inhibitors, including enaside-
nib, with azacitidine for adults unfit for standard induction
chemotherapy is ongoing.
Patient-Oriented
Evidence
No data ● The drug was generally well tolerated and the maximum
tolerated dose was not reached. The most common
treatment-related adverse events were hyperbilirubine-
mia and nausea. One important emergent adverse event
was IDH-inhibitor-associated differentiation syndrome,
though no patients on the study died due to this entity.
● In the Phase II study, 43.1% of red cell transfusion-
dependent patients and 40.2% of platelet-dependent
patients attained transfusion independence.
Cost-Effectiveness No data ● No formal analysis has yet been performed.
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For the unfit patient, the clinician may additionally
consider treatment with low-dose cytarabine (LDAC),
hypomethylating agents (HMA) or tyrosine kinase inhibi-
tors for FMS-like tyrosine kinase internal tandem duplica-
tion (FLT3-ITD) mutated disease. Moreover, in addition to
enasidenib and ivosidenib, an increasing number of tar-
geted therapies are being approved by the FDA.
Midostaurin, approved in 2017 for the treatment of FLT3-
mutated AML, was the first AML drug approved since
2000.15 Gemtuzumab ozogamicin was also approved in
2017 for both newly diagnosed and relapsed/refractory
CD33+ disease.16 Other agents, such as BCL-2 (B-cell
lymphoma 2) directed therapies, novel FLT-3 inhibitors
and other IDH inhibitors are being actively studied and
incorporated into treatment algorithms.17 While the land-
scape of AML treatment is rapidly changing, offering new
hope, patients who are not currently candidates for these
therapies based on either patient or disease factors, or
personal preference, may be managed with hydroxyurea,
best supportive care or enter hospice programs.
IDH mutations and AML
Approximately 8–19% of AML cases carry IDH2 mutations,
with another 7–14% carrying IDH1 mutations.5 IDH is an
enzyme which catalyzes the conversion of isocitrate to
alpha-ketoglutarate in the Tricarboxylic Acid Cycle (TCA)
and peroxisomes. IDH1 is found in the cytoplasm, while
IDH2 is present in mitochondria.18 The two most common
mutated forms of IDH2 seen in myeloid neoplasms are
IDH2-R140 and IDH2-R172, with IDH2-R140 being the
more common; the mutations occur at conserved arginine
residues.19,20 The mutant forms of the enzyme are able to
produce an oncogenic product called R-2-hydroxyglutarate
(2-HG) from alpha-ketoglutarate. 2-HG accumulates and
arrests DNA and histone demethylation pathways (many of
which are dependent on alpha-ketoglutarate), thereby stop-
ping hematopoietic differentiation.21
IDH1/2 mutations are believed to occur early in leuke-
mogenesis. In fact, they are present in 5% of myelodysplas-
tic syndrome cases and occasionally in myeloproliferative
neoplasms, further supporting that they can be present in pre-
leukemic states.18,22,23 IDH1/2 mutants are frequently exclu-
sive of each other, though myeloid malignancies with both
have been described.23,24 IDH mutant cells also frequently
retain a copy of the wild-type (WT) allele.22 Interestingly,
IDH mutations appear to also be exclusive of mutations in
TET2, another enzyme involved in epigenetic regulation.22
IDH1/2 mutations, by increasing the cell concentrations of
2-HG, inhibit TET2 enzymes and similarly cause
hypermethylation.22,25 Studies have additionally shown that
IDH mutations are nearly exclusive of Wilms tumor 1 muta-
tions (WT1). WT1 is a transcription factor which physically
interacts with TET2. Mutant WT1 interferes with normal
TET2 function and therefore cause a similar hypermethyla-
tion phenotype.19,26,27 Thus, IDH, TET2 andWT1 mutations
alter the epigenetic expression of cells in analogous ways;
these are shown in Figure 1.28 Mutant WT1, specifically, is
very commonly overexpressed in AML; its presence and
levels may be useful markers for detection of minimal resi-
dual disease as well as prognostication.27,29,30 Given that
IDH and WT1 do not frequently co-occur, this may be
a less useful strategy in IDH-mutated disease.
2-HG has additional effects on the cell, including
alterations of hypoxia-inducible factor (HIF)
pathways.25 HIFs respond to low oxygen conditions
and activate transcription, particularly in genes which
participate in cell proliferation. Aberrant HIF expres-
sion in the absence of hypoxia has been noted in
tumorigenesis. HIF is modulated by factor inhibiting
HIF (FIH), which requires alpha-ketoglutarate for
activity. Thus, it is proposed that 2-HG may inhibit
FIH and increase HIF expression, and therefore mod-
ulate cell proliferation. However, there are various
factors which may influence HIFs and this relationship
continues to be studied.25
IDH mutations have been detected with increased fre-
quency in older individuals, and appear to have increased
presence in AML with normal karyotype and intermediate-
risk cytogenetics groups.31 Additionally, links with co-
occurring NPM1 and FLT3-ITD mutations have been
reported.24 Overall, the prognostic value of IDH mutations
remains unclear at this time and more data are necessary,
though the prognostic impact of co-occurring NPM1 and
FLT3-ITD appear to supersede IDH status.23,32 It should
be noted that studies that have examined prognostic impact
of IDH mutations thus far studied different patient popula-
tions and, at times, used different designations of IDH
status (for example, combining IDH1/IDH2 mutations,
or, combining IDH2-R140 and IDH1-R172 under
a single designation). Each of these mutant IDH subtypes
may need to be studied individually to truly ascertain
prognostic value.24
Currently, there are two approved medications target-
ing IDH—Ivosidenib, targeting IDH1, and Enasidenib,
targeting IDH2.7,8 We present the available data on
enasidenib.
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Enasidenib
Preclinical data
In addition to further elucidating the pathogenic
mechanisms of mutant IDH1/2, preclinical data on ena-
sidenib offered new potential in AML therapy. Using
2-HG levels as a surrogate of drug activity, Yen et al
were first able to use enasidenib to lower 2-HG levels
and induce differentiation in an IDH2 mutant TF-1
erythroleukemia cell line, suggesting that the presence
of an IDH2 mutation blocked erythropoietin-dependent
cellular maturation. This was then expanded to show
that enasidenib reduced 2-HG levels in AML blasts ex
vivo. Further, in mouse xenograft models, enasidenib
was able to lower 2-HG by more than 90% and success-
fully reestablish myeloblast differentiation. In primary
human AML xenografts, enasidenib-treated mice
showed dramatic results, including 2-HG levels which
approached normal, with 2 to 35-fold reduction in blasts
on bone marrow analysis on day 38 of treatment, while
untreated mice displayed human AML cells dissemi-
nated to both hematopoietic and nonhematopoietic
organs. It was also noted that enasidenib is not cytotoxic
to IDH2 mutant cells; rather, it induces a differentiation
effect, and mature neutrophils which develop in cells
treated with enasidenib continue to carry the mutant
allele.33
Based on the successes of preclinical studies, a multi-
center Phase I/II trial was initiated by Agios and Celgene,
ultimately leading to approval of enasidenib.7 Below, we
review the prominent findings, including results and toxi-
cities. The Phase III trial is currently ongoing.34
Formulation
Enasidenib is an oral, small molecule agent, currently
approved to be taken at a dose of 100 mg daily.6,7,35
Pharmacokinetics/pharmacodynamics
Enasidenib has a half-life of 137 hrs after multiple doses
and reached steady state by cycle 2 within the Phase I/II
study (28-day cycles); this study additionally established
100 mg as efficacious in maintaining steady-state drug
concentrations. Patients treated with 100 mg daily achieved
a median 93% plasma reduction of 2-HG in those with
IDH2-R140 mutations, and a median of 28% (though with
a maximum of 94% plasma reduction of 2-HG) in IDH2-
R172 mutated AML.6
Figure 1 Hypermethylation phenotype in acute myeloid leukemia (AML). IDH1/2, TET2 and WT1 mutations are often mutually exclusive, but similarly lead to
hypermethylation and arrest of differentiation.
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Enasidenib is metabolized via CYP and UGTenzymes. It
can notably induce enzymes CYP3A4 and CYP2B6.
However, the overall effects on other medications are not
clear at this time, as it also inhibits some hepatic enzymes. As
such, caution should be exercised in regard to medication
interactions. For example, enasidenib can both increase and
decrease oral contraception concentrations. In terms of car-
diac pharmacodynamics, enasidenib is not QT prolonging.36
Trial description
The Phase I/II trial enrolled 239 patients. 113 patients were
in the dose-escalation phase, during which doses of either
30, 50, 75, 100 or 150 mg were administered twice per day,
or doses of 50, 75, 100, 150, 200, 300, 450 and 650 mg once
per day; all were administered in continuous 28-day cycles.
126 patients were enrolled in the 4-arm expansion phase
using the 100 mg once daily dose, which was chosen due to
good steady-state drug concentrations as well as ample
clinical activity. The expansion phase compared patients
who were 60 years or older with relapsed/refractory AML
(including those who have relapsed after allogeneic hema-
topoietic stem cell transplant), patients younger than 60 who
were not transplanted but who had relapsed/refractory AML,
age 60 or older and not candidates for induction chemother-
apy, or patients who were not eligible for the other
expansion arms. Notably, the median age among all patients
on the trial was 70.6
In the overall study enrollment, 27% of patients were
older than 75, with 24% among those who received
100 mg enasidenib daily. Notably, 26% of patients
received greater than 3 prior AML treatments (22% in
the enasidenib 100 mg subgroup). 18% of patients had
an ECOG score of 2 (15% in the enasidenib 100 mg
subgroup); most patients had an ECOG of 0 or 1.37
Though the authors did not report additional medical
comorbidities for these patients, the represented group
included many elderly and relapsed/refractory patients
(including 16% of those who relapsed post-transplant),
thus studying a vulnerable population of AML patients.37
Efficacy
The results of the Phase I/II trial of Enasidenib are summar-
ized in Table 1. The overall response rate (ORR, defined as
complete remission, complete remission with incomplete
count recovery, partial remission and morphological leuke-
mia free state) was 40.3% in relapsed/refractory disease; for
the group which received 100 mg daily, the ORR was
38.5%. The overall complete remission rate in patients
with relapsed/refractory disease was 19.3%. Clinical activity
was seen at all enasidenib dose levels tested.
Table 1 Hematologic response, time to response and response duration of patients with relapsed/refractory acute myeloid leukemia
(AML) in the Phase II trial of Enasidenib
Response Enasidenib 100 mg
(n=109)
Median
(range)
All doses (n=176) Median
(range)
No. % 95% CI No. % 95% CI
ORR 42 38.5 29.4–48.3 71 40.3 33.0–48.0
Best Response
Complete remission (CR) 22 20.2 13.1–28.9 34 19.3 13.8–25.9
CR with incomplete hematologic recovery/CR with
incomplete platelet recovery
7 6.4 12 6.8
Partial remission 3 2.8 11 6.3
Morphologic leukemia-free state 10 9.2 14 8.0
Stable disease 58 53.2 85 48.3
Progressive disease 5 4.6 9 5.1
Not evaluable 2 1.8 3 1.7
Time to first reponse, mo 1.9
(0.5–9.4)
1.9
(0.5–9.4)
Duration of response, mo 3.8–9.7 5.6 3.9–7.4 5.8
Time to CR, mo 3.7
(0.7–11.2)
3.8
(0.5–11.2)
Duration of response in patients who attained CR, mo 5.3–not
reached
8.8 6.4–not
reached
8.8
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Across the entire study population, those with IDH2-
R140 mutations had an ORR of 35.4%, and those with
IDH2-R172 mutations had an ORR of 53.3%. The CR rate
for IDH2-R140 disease was 17.7% and IDH2-R172 dis-
ease, 24.4%. Approximately three-fourths of the study
population had IDH2-R140 mutations, and one-fourth
had IDH2-R172 mutations.6
87.3% of patients who ultimately responded to therapy
saw a response by cycle 5, while 82.4% of patients who
achieved complete remission did so by cycle 7. The med-
ian time to first response was 1.9 months, notably with
a wide range of 0.5–9.4 months. This suggested the impor-
tance of continuing enasidenib therapy for at least 5–6
cycles, as more than half of the patients in this study
achieved their best response after cycle 5.37
Importantly, enasidenib showed an improvement in
survival. Among patients with R/R leukemia, the overall
median survival was 9.3 months, while for those who
achieved CR or PR, survival was 19.7 and 14.7 months,
respectively.6 Among patients who received >3 prior AML
therapies, estimated overall median survival was 7
months.37 This is compared with a median survival of
4–8 months in all relapsed/refractory disease, depending
on therapy.11,38 Moreover, approximately 9% of R/R AML
patients proceeded to transplant at the time of data cut-off;
median overall survival for this group was 23.6
months.6,37
Predictive biomarkers
2-HG, as the oncometabolite of mutant IDH, was investi-
gated as a potential biomarker. In preclinical studies, Yen
et al monitored 2-HG level reduction through various mod-
els, noting in the ex vivo model of blasts that reduction of
2-HG levels was less robust in IDH2-R172 mutants versus
R140. Similarly, the Phase I/II study for enasidenib found
that patients with IDH2-R140 mutations had a median 93%
reduction in 2-HG levels (maximum 99%), while patients
with IDH2-R172 had a median 28% reduction (maximum
94%). However, as stated previously, both patients with
IDH2-R140 disease and IDH2-R172 showed a CR of
17.7% and 24.4%, respectively, initially suggesting that
2-HG levels did not correlate with response. Further analy-
sis of patients with IDH2-R140 mutated disease showed
that all patients achieved robust 2-HG reductions, even non-
responders, making 2-HG levels an unreliable biomarker in
these patients. Conversely, greater reductions of 2-HG
levels correlated with improved response in patients with
IDH2-R172 mutations.37 2-HG levels, therefore, may be
a better predictive biomarker for IDH2-R172 disease than
for IDH2-R140, although enasidenib may also have other
mechanisms that are of clinical importance independent of
2-HG reduction.6,37 This represents an active area of
investigation.
Molecular remission
Recently, IDH2 variant allele frequency (VAF) was analyzed
for patients in the Phase I/II trial.37 Data were available for
101 R/R AML patients. IDH2 VAF mean values were simi-
lar for patients with IDH2-R140 and IDH2-R172 mutations.
Of the 101, 12 patients (11.9%), all with IDH2-R140 muta-
tions, achieved molecular remission during enasidenib treat-
ment. Of these 12, 83.3% achieved CR, 8.3% achieved CRp
and 8.3% achieved PR. Among all patients on the trial who
attained CR, survival was not different for those who
attained molecular remission versus those who did not.
Among the 23 patients with IDH2-R172 (22.7% of total
cohort available for analysis), 2 patients (8.7%) achieved
IDH2-R172 VAF levels <2%, both of whom had CR. These
data suggest that while molecular remission is not necessary
to achieve CR, its presence may be predictive, and also
underscores the importance of molecular monitoring over
time.37 Moreover, it will be important to elucidate how
enasidenib, as a non-cytotoxic agent, is able to induce mole-
cular remissions in certain patients. Knowing this mechan-
ism may help identify patients who may gain greater benefit
from enasidenib, as well as suggest additional synergistic
therapies.
Safety
During the dose-escalation portion of the trial, the maximum
tolerated dose was not reached. At higher doses, the drug
was less well tolerated, and 5 of 7 patients in the 650 mg
group were dose modified or reduced; these events did not
qualify as a dose limiting toxicity (DLT). 238 of 239 patients
experienced a treatment-emergent adverse event (TEAE),
with 192 (82%) experiencing a treatment-related TEAE.
The most common treatment-related TEAEs were indir-
ect hyperbilirubinemia (38%) and nausea (23%). Other
common TEAEs included fatigue, diarrhea, decreased
appetite and vomiting. We review selected TEAEs in
Table 2. 41% of patients had grade 3 to 4 TEAEs, again,
most commonly indirect hyperbilirubinemia, but addition-
ally, grade 3 to 4 IDH-inhibitor-associated differentiation
syndrome (IDH-DS) was seen in 6%. IDH-DS of any grade
occurred in 10% of patients. Despite these, enasidenib was
discontinued in only 5% of patients.
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Of note, enasidenib-induced hyperbilirubinemia does not
reflect intrinsic liver injury. The proposed mechanism is that
enasidenib inhibits UGT1A1 enzyme, producing an effect
similar to patients with Gilbert syndrome (congenital defi-
ciency of the enzyme).6 Notably, there is a new trial that is not
yet recruiting whose purpose is to determine pharmacoki-
netics of enasidenib in patients with pre-existing liver dys-
function compared with healthy controls (NCT03290443).39
IDH differentiation syndrome and
leukocytosis
IDH differentiation syndrome (IDH-DS) is a clinical diag-
nosis and requires a high index of suspicion from the
treating physician. The diagnosis is made by excluding
other explanations for signs and symptoms, which include:
dyspnea and hypoxemia, radiological evidence of bilateral
pulmonary infiltrates not responsive to antimicrobials,
worsening peripheral edema, renal failure, fever, rash and
lymphadenopathy.40 It is similar to the syndrome
described in patients receiving all-trans retinoic acid or
arsenic trioxide for acute promyelocytic leukemia (APL).
IDH-DS appears to have a later onset, with a median of 30
days, as compared to 10–12 days for differentiation syn-
drome in patients with APL.40,41
10% of patients enrolled in the trial experienced IDH-
DS, with 2 deaths on the trial initially associated with, but
not directly linked to, the syndrome. For the purposes of
the study, IDH-DS was termed as “retinoic acid syn-
drome” due to the fact that IDH-DS was not yet an
established preferred term. The syndrome has also been
described with the IDH1 inhibitor ivosidenib.42
Further retrospective analysis of study participants and
suspected cases was performed by a differentiation syn-
drome review committee, who concluded that it affected
approximately 12% of patients in the study. The patient
characteristics linked with IDH-DS were as follows: male
sex, fewer previous cancer-directed therapies and less
likely to have less than 20% bone marrow blasts. Of
those affected, 45% of patients interrupted treatment due
to the syndrome, but none stopped permanently. Of note,
30% of patients with IDH-DS required admission to the
intensive care unit, but no death was directly attributed to
IDH-DS. Recommended management of recognized IDH-
DS is dexamethasone 10 mg twice daily, until clinical
improvement. Notably, IDH-DS may be associated with
a positive clinical response.40,42
Leukocytosis was also independently noted in patients
receiving enasidenib, and did not always signify IDH-DS.
Of the patients retrospectively identified with IDH-DS,
39% had concurrent leukocytosis.40 Overall, treatment-
related leukocytosis occurred in 6% of patients.6
Leukocytosis alone can be successfully treated with hydro-
xyurea or drug interruption.36
Recently, the FDA conducted a systematic analysis of
differentiation syndrome associated with both ivosidenib
and enasidenib using the patient data from the Phase I/II
trial, specifically looking at patients who received cur-
rently approved doses of the agents.43 By utilizing an
algorithm as well as individualized review of algorithm-
identified cases, the analysis established a higher incidence
of IDH-DS than previously reported. For enasidenib, the
rate was approximately 19%, higher than the reported rates
in the Phase I/II trial rate (10%) and the retrospective
review (12%). Of the cases identified, 66% were consid-
ered at least grade 3, and 5% were fatal. This suggests that
the main reason for the discrepancy between the initial
reported rate of IDH-DS and the rate in the FDA review
was enhanced detection of previously unidentified cases,
including fatal incidences. Leukocytosis was associated
with 61% of cases. Interestingly, this review also
Table 2 Select treatment-related TEAEs from the Phase II trial of Enasidenib
TEAE Any grade/Enasidenib
100 mg
Any grade/All
doses
Grade 3 or 4/Enasidenib
100 mg
Grade 3 or 4/All
doses
No. % No. % No. % No. %
Hyperbilirubinemia 54 35 90 38 13 8 29 12
Nausea 32 21 56 23 2 1 5 2
Decreased appetite 28 18 42 18 3 2 6 3
Fatigue 18 12 33 14 2 1 6 3
IDH differentiation syndrome 15 10 23 10 11 7 15 6
Anemia 12 8 17 7 10 7 12 5
Leukocytosis 8 5 15 6 2 1 6 3
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suggested that patients with IDH-DS may have lower
response rates.43 Overall, this indicates that continued
vigilance regarding detection of IDH-DS is necessary.
Furthermore, its impact on predicting clinical response is
unclear at this time, and should remain a focus of active
surveillance and research.
Quality of life
No specific analyses on the effect of enasidenib on quality
of life exist. However, as it is generally well tolerated even
in unfit patients, and is an oral agent, it can be postulated
that patients treated with enasidenib may have a better
quality of life than those undergoing standard cytotoxic
chemotherapy. Additionally, in the Phase I/II trial, 43.1%
of RBC transfusion-dependent patients and 40.2% of pla-
telet-dependent patients attained transfusion independence,
which is another important factor that may improve quality
of life in the R/R AML population.37
Cost and cost-effectiveness
To date, there has not been a full cost-effectiveness analysis
published. The whole-sale cost of enasidenib 100 mg tablets
starts from about $25,000 for 30 tablets.44,45 Insurance cover-
age for the drug is available based on insurance-specific
guidelines. Patients who qualify for the Celgene patient
assistance program can obtain the drug for a $25 co-pay.46
Resistance
Acquired resistance to enasidenib therapy has been
reported. Intelkofer et al published a report of two patients
who developed resistance to therapy after initial response.
They identified a new somatic missense mutation in each
patient, Q316E in the first, and I319M in the second, and
then evaluated the effect of these mutations in WT and
IDH2-R140 mutants. In WT IDH, mutations in Q316E
and I319M alone did not induce production of 2-HG.
However, IDH2-R140 mutants with the presence of either
the Q316E or 1319Mmutations continued to produce 2-HG
when exposed to enasidenib. Both Q316E and I319M
are second site mutations which occur in the binding site
of enasidenib and mediate resistance to enasidenib.47
Harding et al recently described isoform switching,
where another form of mutant IDH1/2 emerges after treat-
ment with a targeted inhibitor. In one example, a patient
with myelodysplastic syndrome, subtype refractory anemia
with excess blasts 2, initially completely responded to
enasidenib for seventeen cycles. She then once again
developed excess blasts and elevated 2-HG levels, with
molecular testing identifying a new IDH1-R132C muta-
tion. Further analysis showed that this mutation arose early
during enasidenib treatment.48 Isoform switching was
similarly noted by Quek et al previously, as well as addi-
tional mechanisms of resistance including gain of function
mutations in proliferation genes and transcription factor
mutations.49 Notably, the described patient was then
started on a dual IDH1/IDH2 inhibitor and initially
responded, but subsequently progressed despite adequate
2-HG suppression, indicating that there are likely more
resistance mechanisms that are yet to be identified.48
This also argues for strong consideration of combination
therapy, as resistance to monotherapy can clearly develop.
Future directions
Current trials
Enasidenib continues to be studied in several active and
planned clinical trials. Many of these are outlined in Table 3.
In the following section, we review select enasidenib studies.
Monotherapy, R/R AML
The open-label, randomized Phase III trial for enasidenib
(IDHENTIFY, NCT02577406) is currently ongoing, com-
paring enasidenib with standard therapies in adults older
than 60; estimated recruitment will be approximately 300
participants. The experimental arm is enasidenib alone,
and the conventional care regimen arm includes best sup-
portive care alone, azacitidine alone, as well as low and
intermediate dose cytarabine. The primary endpoint is
overall survival.34
Combination with induction
chemotherapy, treatment-naïve AML
Approximately 134 participants, eligible for standard che-
motherapy, are currently enrolled in the Phase 1 trial
examining treatment-naïve AML with an IDH1/2 mutation
(NCT02632708). The trial will examine the following
combinations: AG-120 (ivosidenib) + cytarabine + daunor-
ubicin or idarubicin; enasidenib + cytarabine + daunoru-
bicin or idarubicin; enasidenib starting day 8+ cytarabine +
daunorubicin or idarubicin. This study aims to determine
the safety and primary efficacy of combining IDH inhibi-
tors with induction agents.50 Preliminary outcomes from
this trial are showing robust results. Among patients with
de-novo AML treated with enasidenib, 73% have achieved
CR, CR with incomplete count recovery (CRi) or CR with
incomplete platelet recovery (CRp). Among those with
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Table 3 Active and recently completed studies of Enasidenib
Study Name Description Phase Status ID
Acute myeloid leukemia (AML)
A Phase 3, Multicenter, Open-label, Randomized
Study Comparing the Efficacy and Safety of AG-
221 (CC-90,007) Versus Conventional Care
Regimens in Older Subjects With Late Stage
Acute Myeloid Leukemia Harboring an Isocitrate
Dehydrogenase 2 Mutation (IDHENTIFY)
An international, multicenter, open-label, rando-
mized trial comparing enasidenib versus conven-
tional care in adults >60. Intervention arm will
receive AG-221 plus best supportive care.
Comparator arms will be treated with best sup-
portive care, azacitidine, low-dose cytarabine or
intermediate-dose cytarabine.
Targets: AML in unfit adults
III Recruiting NCT02577406
A Phase 1, Multicenter, Open-Label, Safety Study
of AG-120 or AG-221 in Combination With
Induction Therapy and Consolidation Therapy in
Patients With Newly Diagnosed Acute Myeloid
Leukemia With an IDH1 and/or IDH2 Mutation
This study combines IDH inhibitors with standard
chemotherapy regimens (cytarabine, idarubicin or
daunorubicin, mitoxantrone and etoposide) in
a total of 6 arms.
Targets: Treatment-naïve AML
I Active, not
recruiting
NCT02632708
A Phase 1b/2 Open-label, Randomized Study of 2
Combinations of Isocitrate Dehydrogenase (IDH)
Mutant Targeted Therapies Plus Azacitidine: Oral
AG-120 Plus Subcutaneous Azacitidine and Oral
AG-221 Plus SC Azacitidine in Subjects With
Newly Diagnosed Acute Myeloid Leukemia
Harboring an IDH1 or an IDH2 Mutation,
Respectively, Who Are Not Candidates to
Receive Intensive Induction Chemotherapy
Treatment-naïve subjects who have an IDH-1 or
IDH-2 mutation ineligible for standard induction
who will receive azacitidine, azacitidine + AG-120,
or azacitidine +AG-221.
Targets: Treatment-naïve AML in unfit adults
I/II Active, not
recruiting
NCT02677922
Phase II Study of the Targeted Mutant IDH2
Inhibitor Enasidenib in Combination With
Azacitidine for Relapsed/Refractory AML
Open-label trial examining enasidenib with azaci-
tidine for R/R AML. One treatment arm that will
receive both azacitidine and enasidenib.
Targets: R/R AML
II Not Yet
Recruiting
NCT03683433
HSCT
A Phase I Study of IDH2 Inhibition Using
Enasidenib as Maintenance Therapy for IDH2-
mutant Myeloid Neoplasms Following Allogeneic
Stem Cell Transplantation
Open-label trial studying enasidenib as mainte-
nance therapy in IDH-2 mutant AML or CMML
undergoing allogeneic hematopoetic stem cell
transplantation.
Targets: AML/CMML w/IDH-2 mutation undergoing
HSCT
I Recruiting NCT03515512
Phase IB Trial of Enasidenib (AG-221)
Maintenance Post Allogeneic Hematopoietic Cell
Transplantation in Patients With IDH2 Mutation
Open-label trial studying enasidenib as mainte-
nance therapy in IDH-2 mutant AML undergoing
allogeneic hematopoetic stem cell transplantation.
Targets: AML w/IDH-2 mutations undergoing HSCT
I Not Yet
Recruiting
NCT03728335
Myelodysplastic Syndrome (MDS)
Targeted Therapy with the IDH2-Inhibitor
Enasidenib (AG221) for High-Risk IDH2-Mutant
Myelodysplastic Syndrome
Non-randomized, open-label trial of Enasidenib
(AG-221) alone or in combination with azacitidine
in MDS.
Arm A: Participants who have never received
a hypomethylating agent who will receive
Azacitidine and Enasidenib.
Arm B: Participants who have received
a hypomethylating drug and have relapsed or
refractory MDS who will receive Enasidenib
alone.
Targets: MDS w/IDH-2 mutation
II Recruiting NCT03383575
A Single-arm Phase II Multicenter Study of IDH2
(AG-221) Inhibitor in Patients With IDH2
Mutated Myelodysplastic Syndrome
An open-label trial examining the overall hema-
tologic response of MDS patients treated with
enasidenib.
Targets: MDS w/IDH-2 mutation
II Not Yet
Recruiting
NCT03744390
(Continued)
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Table 3 (Continued).
Study Name Description Phase Status ID
Broad Molecular-based Studies
European Proof-of-Concept Therapeutic
Stratification Trial of Molecular Anomalies in
Relapsed or Refractory Tumors
(ESMART)
Non-randomized, open-label trial with arms
A-J examining different targeted therapies,
including Enasidenib (arm I).
I/II Recruiting NCT02813135
A Master Protocol for Biomarker-Based
Treatment of AML (The Beat AML Trial)
Non-randomized, open-label trial with 8 treat-
ments arms based on molecular markers. The
study also includes a marker negative sub-study
which will include all screened patients not eligible
for any of the biomarker-driven sub-studies.
I/II Recruiting NCT03013998
Myeloma-Developing Regimens Using Genomics
(MyDRUG) (Genomics Guided Multi-arm Trial of
Targeted Agents Alone or in Combination With
a Backbone Regimen)
Non-randomized, open label trial with 6 treat-
ment arms based on molecular markers for
relapsed refractory multiple myeloma. Patients
will receive a standard myeloma regimen plus
a targeted therapy like enasidenib.
Not Yet
Recruiting
NCT03732703
Pharmacokinetics/Pharmacodynamics
A Phase 1, Open-Label Single-Dose Study to
Assess the Pharmacokinetics of Enasidenib (AG
221, CC 90,007) in Subjects With Moderate and
Severe Hepatic Impairment.
Multi-center, open-label study to assess the phar-
macokinetics of a single 100 mg oral dose of
enasidenib in subjects with moderate and severe
hepatic impairment, and in matched healthy con-
trol subjects with normal hepatic function.
I Recruiting NCT03290443
A Phase 1, 2-Part, Multicenter, Open-label, 3-Arm
Study to Determine the Effect of Enasidenib (CC-
90,007) on the Pharmacokinetics of Single Doses
of Caffeine, Dextromethorphan, Flurbiprofen,
Midazolam, Omeprazole, Digoxin, Rosuvastatin
and Pioglitazone in Subjects With Acute Myeloid
Leukemia Harboring an Isocitrate Dehydrogenase
2 Mutation
Multi-center, open label study to assess the effect
of enasidenib on pharmacokinetics of common
drugs and substances in patients receiving enasi-
denib for AML. Arm 1 will receive caffeine, dex-
tromethorphan, flubiprofen, midazolam and
omeprazole. Arm 2 will receive digoxin and
rosuvastatin. Arm 3 will receive pioglitazone.
I Not Yet
Recruiting
NCT03720366
A Phase 1, Open-Label, Two-Part Study to
Evaluate the Metabolism, Excretion and Absolute
Bioavailability of AG-221 in Healthy Adult Male
Subjects
An open-label study with two experimental arms
examining the absorption, metabolism and excretion
of enasidenib in healthy patients. This armwill receive
100 mg enasidenib and a microtracer and be mon-
itored through urine, fecal and blood
samples. Second arm to determine bioavailability will
receive oral enasidenib, followed by IV solution of
enasidenib and be monitored via serial blood draws.
I Completed NCT02443168
A Phase 1, Single Ascending Dose, Open-label
Study to Evaluate the Pharmacokinetics and Safety
of AG-221 in Healthy Male Japanese Subjects
Relative to Healthy Male Caucasian Subjects
An open-label study to examine pharmacokinetics
and safety. There will be three cohorts with 10
healthy Japanese and 10 healthy Caucasian
patients each. Cohort A will receive 100 mg of
enasidenib. Cohort B will receive 50 mg of enasi-
denib. Cohort C will receive 300 mg of
enasidenib.
I Completed NCT02387866
A Phase 1, Two-Way Crossover Study to Assess
the Pharmacokinetics and Safety of a Single Dose
of AG-221 in Healthy Male Subjects When
Administered Under Fed and Fasted Conditions
An open-label study to examine pharmacokinetics
and safety of enasidenib under fed and fasted
conditions in healthy patients. First arm will
receive 100 mg of enasidenib after a 10 hrs fast.
The second group will receive 100 mg of enasi-
denib 30 mins after the start of a high-fat
breakfast.
I Completed NCT02218346
(Continued)
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secondary AML, 63% have achieved CR, CRi or CRp.
Among all patients treated with enasidenib, 42% have
proceeded to HSCT.51 In regard to adverse events, in the
induction period, 91% of patients in the enasidenib arm
had 1 or greater grade 3 or higher TEAE. The most
common was febrile neutropenia, occurring in 61% of
patients. The next most common were hypophosphatemia
and lung infection, each occurring in approximately 10%
of patients. Approximately 8% of patients experienced
hyperbilirubinemia, which was the most common TEAE
in the Phase I/II enasidenib trial. Additionally, approxi-
mately 30% of enasidenib-treated patients had mutation
clearance after day 28 of induction. Overall, the combina-
tion of enasidenib with induction chemotherapy is show-
ing promising results with acceptable toxicity.51
Combination with HMA, treatment-naïve
AML
A Phase 1/2 randomized for subjects with newly diagnosed
AML harboring either an IDH1 or IDH2 mutation who are
ineligible for standard cytotoxic chemotherapy is expected to
enroll approximately 125 participants (NCT02677922). These
patients will receive azacitidine alone or in combination with
an appropriate IDH inhibitor. Primary outcomes will be dose-
limiting toxicities and adverse events, with secondary out-
comes of overall response rate.52 Preliminary enasidenib data
for 6 patients (3 receiving the approved dose of 100 mg daily,
and 3 receiving 200 mg) showed CR in 2 patients of 4
responders; 2 patients discontinued due to progression of
disease and 1 other for unavailable reasons. Most common
adverse events were nausea and hyperbilirubinemia.53 Given
that mutant IDH-2 induces a hypermethylation phenotype, the
concurrent use of a hypomethylating agent such as azacitidine
with enasidenib may potentially be synergistic, with further
data pending at this time.
Combination with HMA, R/R AML
For R/R AML, a Phase II clinical trial is exploring enasi-
denib and azacitidine combination, recruiting about 50
participants (NCT03683433). Patients will receive the
medications concurrently. Primary objectives will be over-
all response rate, with secondary objectives of determining
event-free survival and overall survival.54
Maintenance post-allo HSCT
A small Phase I trial aims to examine the role of enasidenib in
maintenance therapy or patients receiving transplant for
IDH-2 mutant AML or chronic myelomonocytic leukemia
(CMML) (NCT03728335). Primary outcomes will be max-
imum tolerated dose and dose-limiting toxicities. Secondary
outcomes will be enasidenib-related adverse events, as well
as cumulative incidence of both acute and chronic graft
versus host disease.55
Future preclinical and clinical
investigations
In addition to combinations with induction chemotherapy
and HMA, trials examining the role of enasidenib in
combination with other targeted agents or as
a maintenance agent are of interest.
Table 3 (Continued).
Study Name Description Phase Status ID
Solid Tumors
A Phase 1/2, Multicenter, Open-Label, Dose-
Escalation Study of AG-221 in Subjects With
Advanced Solid Tumors, Including Glioma, and
With Angioimmunoblastic T-cell Lymphoma, That
Harbor an IDH2 Mutation
Multi-center, open-label study to examine the
safety/tolerability of enasidenib in advanced glio-
mas and angioimmunoblastic T-cell lymphoma with
IDH-2 mutations.
Targets: Advanced solid tumors
I/II Completed NCT02273739
Other
Prospective Analysis of Frailty Phenotype
Assessments to Optimize Treatment Strategies
for Older Patients With Hematologic
Malignancies
Non-randomized, open-label trial assessing
whether frailty assessments can be used to pre-
dict outcomes of patients 60 years and older who
undergo chemotherapy or allogeneic stem cell
transplant. Enasidenib will be evaluated as a part
of Arm A, assessing different cancer directed
therapies, including targeted therapies in combi-
nation or alone.
N/A Not Yet
Recruiting
NCT03680677
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Preclinical data showed that mutations in IDH cause
dependence on the anti-apoptotic gene BCL-2 in leukemic
cells, and the BCL-2 inhibitor, venetoclax, demonstrated
significant preclinical activity in mIDH disease.56 In
a recent clinical trial of venetoclax + HMA in treatment-
naïve older AML patients, patients with IDH1/2 mutations
in the venetoclax 400 mg + azacitidine cohort attained
a 90% CR/CRi rate and 100% CR/CRi in the venetoclax
400 mg + decitabine cohort.57 The overall survival was
24.4 months for those with IDH1/2 mutations, but did not
reach statistical significance to predict outcome for this
group.58 Given such robust responses, it may be of interest
to study combinations of enasidenib with venetoclax +
HMA or venetoclax alone. Interestingly, some data sug-
gest that pairing an mIDH inhibitor with venetoclax may
lead to lower response rates by reversing the pathways that
render mIDH AML sensitive.59 However, given the com-
plex molecular landscape of AML, there may be additional
pathways by which a combination of IDH inhibition and
venetoclax may induce durable responses, potentially in
combination with HMA. IDH inhibitors combined with
targeted therapies against FLT3 may be another viable
option. With early success of combining HMA with ena-
sidenib, addition of FLT3 targeted therapy may prove to be
an even more potent combination. While enasidenib is
currently being examined as maintenance post-transplant
(NCT03728335), it could also have a role as maintenance
agent after intensive chemotherapy in patients not going to
transplant, in patients with minimal/measurable residual
disease (MRD) or in patients with molecular relapses.
Additional preclinical and clinical investigations are likely
to address such additional questions to further define the
potential role of enasidenib in the treatment of AML
bearing IDH2 mutations.
Advancing the role of IDH2 molecular
testing
Given the availabilities of new targeted therapies, molecu-
lar testing should be standard in all newly diagnosed AML
and include testing for IDH2.12 Not only the availability,
but also the timeliness of such testing is becoming increas-
ingly important. The BEAT AML trial, designed in part to
assess whether molecular testing could be used to assign
patients to treatment arms within 7 days, has recently
found this to be feasible.60 Of the 210 patients enrolled,
52% were successfully entered into an appropriate sub-
study based on molecular testing and received treatment.
Further, 81 additional patients pursued alternative thera-
pies after treatment assignment, suggesting that molecular
testing could be obtained and used for clinical decision
making within 7 days for a total of 91% of patients
enrolled.60 In the enasidenib arm of this study, 96% of
consented patients received treatment.61 Overall, this
demonstrates that rapid identification of targetable muta-
tions in AML is already both possible and practical, and
further advancements in testing have the potential to make
targeted therapies even more accessible.
Rapid, easily available testing could also accelerate the
use of IDH2 mutations as a marker of MRD. Detection of
certain genetic abnormalities (including IDH2) after treat-
ment has been associated with worse outcomes and an
increased risk of relapse.62 However, the prognostic sig-
nificance of persistent IDH2 mutations in the setting of
specific treatments and/or subsets of AML remains to be
fully elucidated as does the optimal method and cutoff for
detecting IDH2 mutations and the impact of prospectively
treating such patients with enasidenib or other treatment
modalities, such as allotransplant.
Conclusion
The availability of molecular testing and targeted drugs is
transforming the approach to treating newly diagnosed
AML as well as R/R disease, making precision and perso-
nalized medicine a possibility. The emergence of molecu-
lar-based therapy in AML offers new hope, especially to
patients who cannot tolerate standard cytotoxic regimens.
Molecular testing should be done for all newly diagnosed
AML cases, and continue during both treatment and
relapse to identify response, MRD and treatment-
emergent targetable mutations.
Enasidenib is FDA approved for R/R AML,
a promising therapy with a generally favorable side effect
profile that should be considered for patients with IDH2-
mutated AML. Enasidenib’s role in upfront AML therapy
with induction, combination with HMA, combination with
other targeted therapies, as well as post-consolidation or
transplant maintenance remains to be determined, but
additional clinical investigations with enasidenib are likely
to continue to evolve the landscape of AML therapy.
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